Observation on the Analgesic Effect of Different Doses of a Combination of Esketamine and Dexmedetomidine Administered for Percutaneous Endoscopic Transforaminal Discectomy: A Randomized, Double-Blind Controlled Trial

IF 7.4 2区 医学 Q1 CLINICAL NEUROLOGY CNS drugs Pub Date : 2024-04-04 DOI:10.1007/s40263-024-01083-2
Jian-Shun Zhou, Zhen Chen, Ying-Ying Liu, Mao-Lin Zhong, Qiong Zhong, Jun Wei, Qian Hu, Jia-Sheng Wang, Li-Feng Wang
{"title":"Observation on the Analgesic Effect of Different Doses of a Combination of Esketamine and Dexmedetomidine Administered for Percutaneous Endoscopic Transforaminal Discectomy: A Randomized, Double-Blind Controlled Trial","authors":"Jian-Shun Zhou, Zhen Chen, Ying-Ying Liu, Mao-Lin Zhong, Qiong Zhong, Jun Wei, Qian Hu, Jia-Sheng Wang, Li-Feng Wang","doi":"10.1007/s40263-024-01083-2","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Percutaneous endoscopic transforaminal discectomy (PETD) is an effective method for treating lumbar disc herniation, and is typically performed under local anesthesia. However, inadequate analgesia during the procedure remains a concern, prompting the search for a medication that can provide optimal pain control with minimal impact on the respiratory and circulatory systems.</p><h3 data-test=\"abstract-sub-heading\">Objectives</h3><p>The aim of this study was to observe the effects of different doses of esketamine combined with dexmedetomidine on reducing visual analog scale (VAS) scores during surgical interventions.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>One hundred two patients who underwent PETD were randomly divided into a control group (group C: normal saline + dexmedetomidine), an E1 group (0.1 mg kg<sup>−1</sup> esketamine + dexmedetomidine), and an E2 group (0.2 mg kg<sup>−1</sup> esketamine + dexmedetomidine). The primary outcome was the maximum visual analogue scale (VAS) (score: 0 = no pain and 10 = worst pain) at six time points. The secondary outcomes included the Assessment of Alertness/Sedation Scale (OAA/S) score and mean arterial pressure (BP), heart rate (HR), respiratory rate (RR), and oxygen saturation (SpO<sub>2</sub>) at 11 time points. The incidence of adverse reactions during and 24 h after the operation and patient satisfaction with the anesthesia were also recorded.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Compared with those in group C, the VAS scores of patients in groups E1 and E2 were lower at <i>T</i><sub>6</sub>, <i>T</i><sub>7</sub>, and <i>T</i><sub>9</sub> (<i>P</i> &lt; 0.05). From <i>T</i><sub>4</sub> to <i>T</i><sub>10</sub>, the OAA/S scores of the E1 and E2 groups were both lower than those of group C (<i>P</i> &lt; 0.05), and at the <i>T</i><sub>4</sub>–<i>T</i><sub>6</sub> time points, the OAA/S score of the E2 group was lower than that of group E1 (<i>P</i> &lt; 0.05). At <i>T</i><sub>4</sub> and <i>T</i><sub>5</sub>, the HR and BP of patients in groups E1 and E2 were greater than those in group C (<i>P</i> &lt; 0.05). Compared with those in group C, the incidences of intraoperative illusion, floating sensation, postoperative dizziness, and hyperalgesia in groups E1 and E2 were significantly greater (<i>P</i> &lt; 0.01). There was no significant difference in patient RR, SpO<sub>2</sub>, or postoperative satisfaction with anesthesia among the three groups (<i>P</i> &gt; 0.05).</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>The combination of esketamine and dexmedetomidine can reduce VAS scores during certain stages of this type of surgery; it has minimal impact on respiration and circulation. However, this approach is associated with increased incidences of postoperative dizziness and psychiatric side effects, which may also affect patients’ compliance with surgical instructions from medical staff. Patient satisfaction was not greater with dexmedetomidine combined with esketamine than with dexmedetomidine alone.</p><h3 data-test=\"abstract-sub-heading\">Trial Registration</h3><p>http://www.chictr.org.cn. Identifier: ChiCTR2300068206. Date of registration: 10 February 2023.</p>","PeriodicalId":10508,"journal":{"name":"CNS drugs","volume":null,"pages":null},"PeriodicalIF":7.4000,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40263-024-01083-2","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Percutaneous endoscopic transforaminal discectomy (PETD) is an effective method for treating lumbar disc herniation, and is typically performed under local anesthesia. However, inadequate analgesia during the procedure remains a concern, prompting the search for a medication that can provide optimal pain control with minimal impact on the respiratory and circulatory systems.

Objectives

The aim of this study was to observe the effects of different doses of esketamine combined with dexmedetomidine on reducing visual analog scale (VAS) scores during surgical interventions.

Methods

One hundred two patients who underwent PETD were randomly divided into a control group (group C: normal saline + dexmedetomidine), an E1 group (0.1 mg kg−1 esketamine + dexmedetomidine), and an E2 group (0.2 mg kg−1 esketamine + dexmedetomidine). The primary outcome was the maximum visual analogue scale (VAS) (score: 0 = no pain and 10 = worst pain) at six time points. The secondary outcomes included the Assessment of Alertness/Sedation Scale (OAA/S) score and mean arterial pressure (BP), heart rate (HR), respiratory rate (RR), and oxygen saturation (SpO2) at 11 time points. The incidence of adverse reactions during and 24 h after the operation and patient satisfaction with the anesthesia were also recorded.

Results

Compared with those in group C, the VAS scores of patients in groups E1 and E2 were lower at T6, T7, and T9 (P < 0.05). From T4 to T10, the OAA/S scores of the E1 and E2 groups were both lower than those of group C (P < 0.05), and at the T4T6 time points, the OAA/S score of the E2 group was lower than that of group E1 (P < 0.05). At T4 and T5, the HR and BP of patients in groups E1 and E2 were greater than those in group C (P < 0.05). Compared with those in group C, the incidences of intraoperative illusion, floating sensation, postoperative dizziness, and hyperalgesia in groups E1 and E2 were significantly greater (P < 0.01). There was no significant difference in patient RR, SpO2, or postoperative satisfaction with anesthesia among the three groups (P > 0.05).

Conclusion

The combination of esketamine and dexmedetomidine can reduce VAS scores during certain stages of this type of surgery; it has minimal impact on respiration and circulation. However, this approach is associated with increased incidences of postoperative dizziness and psychiatric side effects, which may also affect patients’ compliance with surgical instructions from medical staff. Patient satisfaction was not greater with dexmedetomidine combined with esketamine than with dexmedetomidine alone.

Trial Registration

http://www.chictr.org.cn. Identifier: ChiCTR2300068206. Date of registration: 10 February 2023.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
观察经皮内窥镜经椎间孔椎间盘切除术中使用不同剂量的艾司他敏和右美托咪定组合的镇痛效果:随机双盲对照试验
背景经皮内窥镜经椎间孔椎间盘切除术(PETD)是治疗腰椎间盘突出症的有效方法,通常在局部麻醉下进行。本研究旨在观察不同剂量的艾司卡胺联合右美托咪定对降低手术干预期间视觉模拟量表(VAS)评分的影响。方法 将 120 名接受 PETD 的患者随机分为对照组(C 组:生理盐水 + 右美托咪定)、E1 组(0.1 mg kg-1 esketamine + 右美托咪定)和 E2 组(0.2 mg kg-1 esketamine + 右美托咪定)。主要结果是六个时间点的最大视觉模拟量表(VAS)(评分:0 = 无痛,10 = 疼痛最严重)。次要结果包括警觉性评估/镇静量表(OAA/S)评分和 11 个时间点的平均动脉压(BP)、心率(HR)、呼吸频率(RR)和血氧饱和度(SpO2)。结果与 C 组相比,E1 和 E2 组患者在 T6、T7 和 T9 的 VAS 评分较低(P <0.05)。从 T4 到 T10,E1 组和 E2 组的 OAA/S 评分均低于 C 组(P <;0.05),在 T4-T6 时间点,E2 组的 OAA/S 评分低于 E1 组(P <;0.05)。在 T4 和 T5,E1 组和 E2 组患者的心率和血压均高于 C 组(P < 0.05)。与 C 组相比,E1 组和 E2 组患者术中错觉、漂浮感、术后头晕和痛觉过敏的发生率明显更高(P < 0.01)。三组患者的 RR、SpO2 或术后麻醉满意度无明显差异(P >0.05)。结论埃斯氯胺酮和右美托咪定联合使用可降低此类手术某些阶段的 VAS 评分;对呼吸和循环的影响最小。然而,这种方法会增加术后头晕和精神副作用的发生率,也可能影响患者对医务人员手术指令的依从性。右美托咪定联合艾司氯胺酮的患者满意度并不比单独使用右美托咪定高。试验注册http://www.chictr.org.cn。标识符:ChiCTR2300068206。注册日期:2023年2月10日。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CNS drugs
CNS drugs 医学-精神病学
CiteScore
12.00
自引率
3.30%
发文量
82
审稿时长
6-12 weeks
期刊介绍: CNS Drugs promotes rational pharmacotherapy within the disciplines of clinical psychiatry and neurology. The Journal includes: - Overviews of contentious or emerging issues. - Comprehensive narrative reviews that provide an authoritative source of information on pharmacological approaches to managing neurological and psychiatric illnesses. - Systematic reviews that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement. - Adis Drug Reviews of the properties and place in therapy of both newer and established drugs in neurology and psychiatry. - Original research articles reporting the results of well-designed studies with a strong link to clinical practice, such as clinical pharmacodynamic and pharmacokinetic studies, clinical trials, meta-analyses, outcomes research, and pharmacoeconomic and pharmacoepidemiological studies. Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in CNS Drugs may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.
期刊最新文献
Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study. Efficacy of Cariprazine in the Psychosis Spectrum: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials in Schizophrenia and Bipolar Disorder. Research Progress on NMDA Receptor Enhancement Drugs for the Treatment of Depressive Disorder. A Multicenter, Open-Label Study to Evaluate the Long-term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder. Recent Advances in Pharmacologic Treatments of Drug-Resistant Epilepsy: Breakthrough in Sight.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1